BC Week In Review | Aug 1, 2016
Company News

ANI Pharmaceuticals sales and marketing update

ANI launched a generic version of Nilandron nilutamide from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) in the U.S. The oral testosterone blocker is marketed to treat metastatic prostate cancer. Under a 2013 deal, Sanofi granted Covis...
BC Week In Review | Dec 7, 2015
Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia completed its acquisition of fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for $3.1 billion, including $1.4 billion in debt. The acquisition consists of L800 million ($1.2 billion) in cash, $47.5...
BC Week In Review | Oct 12, 2015
Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia will acquire fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for up to $3.6 billion, including debt. The acquisition consists of L800 million ($1.2 billion) in cash and 8.5 million of...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
BC Week In Review | Sep 28, 2015
Financial News

Concordia Healthcare completes follow-on

Concordia Healthcare Corp. (TSX:CXR; NASDAQ:CXRX), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date completed: 2015-09-24   Type: Follow-on   Raised: $520 million   Shares: 8 million   Price: $65   Shares after offering: 42.3...
BC Week In Review | Jun 1, 2015
Company News

Covis, Concordia Healthcare deal

Concordia completed its acquisition of Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash (see BioCentury, March 16). Covis Pharma S.a.r.l. , Zug, Switzerland   Concordia Healthcare Corp. (TSX:CXR;OTCQX:CHEHF), Oakville,...
BC Week In Review | Apr 20, 2015
Financial News

Concordia Healthcare completes private placement of senior notes

Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date completed: 2015-04-13   Type: Private placement of senior notes   Raised: $735 million   Investor: Institutional investors   Note: The unsecured...
BC Week In Review | Apr 13, 2015
Financial News

Concordia Healthcare proposes private placement of senior notes

Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date announced: 2015-04-06   Type: Private placement of senior notes   To be raised: $610 million   Shares: TBD   Price: TBD...
BC Week In Review | Apr 13, 2015
Financial News

Concordia Healthcare proposes private placement

Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date announced: 2014-04-08   Type: Private placement   To be raised: C$368 million ($295.4 million)   Shares: 4.3 million   Price: C$85...
BC Week In Review | Mar 16, 2015
Company News

Covis, Concordia Healthcare deal

Concordia will acquire Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash. Covis expects to record $47-$52 million in revenue related to the acquired products. The deal includes Nilandron...
Items per page:
1 - 10 of 12
BC Week In Review | Aug 1, 2016
Company News

ANI Pharmaceuticals sales and marketing update

ANI launched a generic version of Nilandron nilutamide from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) in the U.S. The oral testosterone blocker is marketed to treat metastatic prostate cancer. Under a 2013 deal, Sanofi granted Covis...
BC Week In Review | Dec 7, 2015
Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia completed its acquisition of fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for $3.1 billion, including $1.4 billion in debt. The acquisition consists of L800 million ($1.2 billion) in cash, $47.5...
BC Week In Review | Oct 12, 2015
Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia will acquire fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for up to $3.6 billion, including debt. The acquisition consists of L800 million ($1.2 billion) in cash and 8.5 million of...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
BC Week In Review | Sep 28, 2015
Financial News

Concordia Healthcare completes follow-on

Concordia Healthcare Corp. (TSX:CXR; NASDAQ:CXRX), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date completed: 2015-09-24   Type: Follow-on   Raised: $520 million   Shares: 8 million   Price: $65   Shares after offering: 42.3...
BC Week In Review | Jun 1, 2015
Company News

Covis, Concordia Healthcare deal

Concordia completed its acquisition of Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash (see BioCentury, March 16). Covis Pharma S.a.r.l. , Zug, Switzerland   Concordia Healthcare Corp. (TSX:CXR;OTCQX:CHEHF), Oakville,...
BC Week In Review | Apr 20, 2015
Financial News

Concordia Healthcare completes private placement of senior notes

Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date completed: 2015-04-13   Type: Private placement of senior notes   Raised: $735 million   Investor: Institutional investors   Note: The unsecured...
BC Week In Review | Apr 13, 2015
Financial News

Concordia Healthcare proposes private placement of senior notes

Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date announced: 2015-04-06   Type: Private placement of senior notes   To be raised: $610 million   Shares: TBD   Price: TBD...
BC Week In Review | Apr 13, 2015
Financial News

Concordia Healthcare proposes private placement

Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date announced: 2014-04-08   Type: Private placement   To be raised: C$368 million ($295.4 million)   Shares: 4.3 million   Price: C$85...
BC Week In Review | Mar 16, 2015
Company News

Covis, Concordia Healthcare deal

Concordia will acquire Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash. Covis expects to record $47-$52 million in revenue related to the acquired products. The deal includes Nilandron...
Items per page:
1 - 10 of 12